Meeting
2024 ASCO Annual Meeting
Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE) led to higher response, OS, and PFS in patients with transplant-eligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Authors
Mody Amin
University at Buffalo, Buffalo, NY
Mody Amin , Alex Niu , Kristopher Attwood , Anthony George , Farhan Azad , Jerry Wong , Grant Schofield , Dorothy C. Pan , Sheila N. J. Sait , Anne Marie W. Block , Eugene Przespolewski , Carolyn Connors , Joseph Demarco , Keryn Gauch , Nikolina Gjorgievski , Michael Johnson , Linda Manth , Kenneth McWhite , Matthew Joseph Cortese , Francisco J. Hernandez-Ilizaliturri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 7042)
DOI
10.1200/JCO.2024.42.16_suppl.7042
Abstract #
7042
Poster Bd #
25
Abstract Disclosures
Similar Posters
First Author: Jennifer Leigh Crombie
Poster
2022 ASCO Annual Meeting
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.
First Author: Nancy L. Bartlett
Poster
2022 ASCO Annual Meeting
TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).
First Author: Krish Patel
Poster
2022 ASCO Annual Meeting
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
First Author: Joshua Brody